Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The rationale for prophylactic cancer vaccines and need for a paradigm shift

Cancer Gene Therapy volume 13, pages 725–731 (2006)Cite this article

Abstract

This review summarizes clinical experience with infectious disease vaccines and data from animal tumor models that support a paradigm shift for cancer vaccines from therapeutic to prevention applications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Dunn BK, Wickerham DL, Ford LG . Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005; 23: 357–367.

    Article  Google Scholar 

  2. Parnes HL, Thompson IM, Ford LG . Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005; 23: 368–377.

    Article  Google Scholar 

  3. Hawk ET, Levin B . Colorectal cancer prevention. J Clin Oncol 2005; 23: 378–391.

    Article  Google Scholar 

  4. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M . Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–2029.

    Article  CAS  Google Scholar 

  5. Oettgen HF, Old LJ . History of cancer immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds). Biological Therapy of Cancer. JB Lippencott: Philadelphia, PA, 1991, pp 87–119.

    Google Scholar 

  6. Lamm DL . Efficacy and safety of bacille Calmette–Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31 (Suppl 3): S86–S90.

    Article  Google Scholar 

  7. Kirkwood J . Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29 (3 Suppl 7): 18–26.

    Article  CAS  Google Scholar 

  8. Rosenberg SA . Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 2000; 6 (Suppl 1): S2–S7.

    PubMed  Google Scholar 

  9. Levy R, Miller RA . Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annu Rev Med 1983; 34: 107–116.

    Article  CAS  Google Scholar 

  10. Sobol RE, Dillman RO, Halpern S, Shawler DL, Hagan P, Ferrone S et al. Serotherapy and radioimmunodetection of tumors with monoclonal antibodies. In: Moloy P, Nicolson G (eds). Cellular Oncology: New Approaches in Biology, Diagnosis and Treatment. Praeger Press: New York, 1983, pp 256–281.

    Google Scholar 

  11. Levy R . A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol 2000; 37 (4 Suppl 7): 43–46.

    Article  CAS  Google Scholar 

  12. Finn RS, Slamon DJ . Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif 2003; 21: 223–233.

    Article  CAS  Google Scholar 

  13. Mendelsohn J . Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother 2003; 52: 342–346.

    PubMed  Google Scholar 

  14. Lollini PL, Forni G . Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 2002; 51: 409–416.

    Article  CAS  Google Scholar 

  15. Finn OJ . Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630–641.

    Article  CAS  Google Scholar 

  16. Hellstrom KE, Hellstrom I . Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines 2003; 2: 517–532.

    Article  CAS  Google Scholar 

  17. Blattman JN, Greenberg PD . Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200–205.

    Article  CAS  Google Scholar 

  18. Hsueh EC, Morton DL . Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003; 13: 401–407.

    Article  CAS  Google Scholar 

  19. Ragupathi G, Livingston P . The case for polyvalent cancer vaccines that induce antibodies. Expert Rev Vaccines 2002; 1: 193–206.

    Article  CAS  Google Scholar 

  20. Herlyn D, Birebent B . Advances in cancer vaccine development. Ann Med 1999; 31: 66–78.

    Article  CAS  Google Scholar 

  21. Whiteside TL, Vujanovic NL, Herberman RB . Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221–244.

    CAS  PubMed  Google Scholar 

  22. Dallal RM, Lotze MT . Immunotherapy of metastasis. Surg Oncol Clin N Am 2001; 10: 433–447.

    Article  CAS  Google Scholar 

  23. Houghton AN, Guevara-Patino JA . Immune recognition of self in immunity against cancer. J Clin Invest 2004; 114: 468–471.

    Article  CAS  Google Scholar 

  24. Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 2002; 99: 12275–12280.

    Article  CAS  Google Scholar 

  25. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543.

    Article  CAS  Google Scholar 

  26. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909–2914.

    Article  CAS  Google Scholar 

  27. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403.

    Article  CAS  Google Scholar 

  28. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP . Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 2002; 9: 464–469.

    Article  CAS  Google Scholar 

  29. Ribas A, Butterfield LH, Glaspy JA, Economou JS . Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415–2432.

    Article  CAS  Google Scholar 

  30. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Therapy 2002; 9: 345–352.

    Article  CAS  Google Scholar 

  31. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA . Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92: 11993–11997.

    Article  CAS  Google Scholar 

  32. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14631–14638.

    Article  CAS  Google Scholar 

  33. Lam JS, Belldegrun AS, Figlin RA . Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2004; 4: 1081–1096.

    Article  CAS  Google Scholar 

  34. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA–liposome complexes. Proc Natl Acad Sci USA 1996; 93: 15388–15393.

    Article  CAS  Google Scholar 

  35. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125–133.

    Article  CAS  Google Scholar 

  36. Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002; 51: 9–14.

    Article  CAS  Google Scholar 

  37. Farzaneh F, Habib N, Walden P . Cancer gene therapy: new horizons in the East International Society for Cancer Gene Therapy, Singapore, 20–22 February 2004. Cancer Immunol Immunother 2004; 53: 1052–1053.

    Article  Google Scholar 

  38. Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J et al. T-cell recognition of human melanoma antigens. J Immunother 1993; 14: 88–93.

    Article  CAS  Google Scholar 

  39. Chen JJ, Saeki Y, Shi LF, Kohler H . Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined ‘internal image’ anti-idiotypes and chemotherapy. J Immunol 1989; 143: 1053–1057.

    CAS  PubMed  Google Scholar 

  40. Antonia S, Mule JJ, Weber JS . Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004; 16: 130–136.

    Article  CAS  Google Scholar 

  41. Egen JG, Kuhns MS, Allison JP . CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611–618.

    Article  CAS  Google Scholar 

  42. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S . Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003; 24: 335–342.

    Article  CAS  Google Scholar 

  43. Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002; 1: 1129–1137.

    CAS  PubMed  Google Scholar 

  44. Dalgleish AG . Cancer vaccines as a therapeutic strategy. Expert Rev Vaccines 2004; 3: 665–668.

    Article  CAS  Google Scholar 

  45. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ et al. DNA vaccines to attack cancer. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14646–14652.

    Article  CAS  Google Scholar 

  46. Henderson RA, Mossman S, Nairn N, Cheever MA . Cancer vaccines and immunotherapies: emerging perspectives. Vaccine 2005; 23: 2359–2362.

    Article  CAS  Google Scholar 

  47. Dietzschold B, Ertl HC . New developments in the pre- and post-exposure treatment of rabies. Crit Rev Immunol 1991; 10: 427–439.

    CAS  PubMed  Google Scholar 

  48. Jenner E . An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow-pox. Sampson Low: Soho, London, 1798.

  49. Gravitt PE, Shah KV . A Virus-based vaccine may prevent cervical cancer. Curr Infect Dis Rep 2005; 7: 125–131.

    Article  Google Scholar 

  50. Franco EL, Harper DM . Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388–2394.

    Article  CAS  Google Scholar 

  51. Hilleman MR . Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003; 21: 4626–4649.

    Article  CAS  Google Scholar 

  52. Ostrand-Rosenberg S . Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16: 143–150.

    Article  CAS  Google Scholar 

  53. De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004; 64: 4328–4337.

    Article  Google Scholar 

  54. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003; 9: 1413–1417.

    Article  CAS  Google Scholar 

  55. Greiner JW, Zeytin H, Anver MR, Schlom J . Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62: 6944–6951.

    CAS  PubMed  Google Scholar 

  56. Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 2004; 64: 3668–3678.

    Article  CAS  Google Scholar 

  57. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001; 167: 4560–4565.

    Article  CAS  Google Scholar 

  58. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB . An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100: 15101–15106.

    Article  CAS  Google Scholar 

  59. Garber JE, Offit K . Hereditary cancer predisposition syndromes. J Clin Oncol 2004; 23: 276–292.

    Article  Google Scholar 

  60. Greenwald P . Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. J Cell Biochem Suppl 1996; 25: 29–36.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sidney Kimmel Cancer Center, Introgen Therapeutics Inc., Houston, TX, USA

    R E Sobol

Authors
  1. R E Sobol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R E Sobol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sobol, R. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 13, 725–731 (2006). https://doi.org/10.1038/sj.cgt.7700950

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700950

Keywords

This article is cited by

Search

Advanced search

Quick links